Takeover bid for Arana
Friday, 27 February, 2009
Arana Therapeutics is in discussions with an unnamed party about a possible takeover bid for the cash-rich company.
Arana, itself the result of a merger between Evogenix and Peptech, has a full and promising pipeline and a very strong cash position of $175 million.
It discontinued its age-related macular degeneration project PMX53 recently, but has strong candidates in inflammatory diseases. Lead candidate ART621, an anti-TNF antibody, is nearing the end of a Phase II trial for psoriasis and is beginning Phase II for rheumatoid arthritis.
The company’s market capitalisation is a very healthy $190 million and its finances strong enough to have carried out a share buy-back.
The company said it would make an announcement on both the bid and the search for a new CEO in due course.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
